RE:RE:CD8+ TiLs and T-cell exhaustion
With respect to ONCY partnerships it is important to know that while BioNTech is involved with Genentech (Roche) in the development of mRNA vaccine in the treatment of resected pancreatic cancer in combination with Roche's checkpoint inhibitor atezolizumab (Tecentrq) - BioNTech is also partnered with Pfizer in the development and distribution of Pfizer's Covid-19 vaccine (Comirnaty) .
In March 2024 Pfizer announced that the IRA was driving the company's focus towards biologics and not small molecules, increasing Pfizer's focus on late-state biologics development companies like ONCY, with pelareorep's drug platform, which has demonstrated the generation and expansion of T cell clones, promoted tumor infiltration of CD8+ TiL cells, and increased the CelTIL score, a measure of tumor cellularity and inflammation associated with favorable clinical outcomes.
As posted before, besides being able to overcome an immunosuppressive TME, pelareorp is a critical 'facilitator' in 'priming' the adaptive immune system in advance of PD-1 blockade, thus turning a 'cold' tumor into a 'hot' tumor that is more much conducive for PD-1 blockade, and a more effective I/O therapy than either agent alone.
https://www.biospace.com/article/ira-drives-pfizer-s-decision-to-focus-on-biologics-not-small-molecules/